LMP1 reduces serum dependency, contact inhibition and anchorage-dependent growth (Wang et al., 1985) . In epithelial cells, LMP1 inhibits dierentiation (Dawson et al., 1990; Wilson et al., 1990) and modulates the phenotype of B lymphoblastoid cells by inducing B-lymphocyte activation markers and cell adhesion molecules (Wang et al., 1990) . In addition, LMP1`protects' B lymphocytes from apoptosis, in part by inducing the expression of the bcl-2 oncogene (Henderson et al., 1991) .
To further investigate the contribution of LMP1 gene expression to the development of a neoplastic phenotype, we have attempted to down-regulate the gene by devising a synthetic antisense oligodeoxynucleotide that, by binding to a target sequence on LMP1 mRNA, would prevent its translation. We have synthesized several, non-chemically modi®ed antisense oligodeoxynucleotides directed to dierent potential target sequences within the translation initiation region of EBV LMP1 mRNA. The eects of the incubation of LMP1 antisense oligodeoxynucleotides were studied on B95.8 cells, EBV transformed marmoset leukocytes (Miller et al., 1972) . We have found that one oligomer, denominated AS2, encompassing the predicted translation initiation site of LMP1 mRNA expressed in B95.8 cells (see Table 1 ), inhibits cell proliferation, leads to a substantial loss of LMP1 mRNA and signi®cantly decreases the intracellular concentration of LMP1 protein as reported below.
In order to examine the eect of LMP1 antisense oligodeoxynucleotide AS2 on cellular proliferation, the growth rate of B95.8 cells was studied in the presence of AS2 oligomers. A non-sense LMP1 sequence, termed Sc2 (a randomly scrambled version of the AS2 sequence), was used as a control. Figure 1a shows that LMP1 AS2 oligomers, added to the cell cultures at 24 h intervals to maintain oligomer concentrations at about 20 mM, markedly inhibited the proliferation of B95.8 cells during a 4 day incubation. In contrast, treatment of the cells with the same concentration of Sc2 oligodeoxynucleotides, had little eect on the proliferation of B95.8 cells. Under the conditions used in these experiments, the inhibition of cell growth was maximal at 48 h, the values ranging between 30 and 70% ( Figure 1b) . When B95.8 cells were treated with LMP1 oligomers in increasing concentrations (in the range between 5 and 60 mM), dose dependent inhibition of cell proliferation by AS2 was observed for antisense (Biological Industries) were diluted in the same medium to 2.5610 5 ml and seeded in 0.2 ml/well in 96-well¯at-bottomed microtiter plates. At 0, 24, 48 and 72 h, LMP1 oligodeoxynucleotides were added to a ®nal concentration of 20 mM. Cell counts were assessed daily by trypan blue exclusion. Time course of B95.8 cell growth in the absence (±&±) or in the presence of either LMP1 AS2 (±*±) or LMP1 non-sense (±*±) oligodeoxynucleotides. (b) Per cent inhibition of B95.8 proliferation. Cells were cultured as in (a). Cell counts were converted to per cent inhibition (Wickstrom et al., 1988) Figure 1c ). The inhibition apparently does not exceed 75%. This can be explained by the de®ned turnover rate of the oligonucleotide inside the cell and by the uptake of the oligomer that, under our experimental circumstances, will reach saturation. During the 4 days of culture in the presence of either antisense or non-sense LMP1 oligomers, B95.8 cell viability remained greater than 80% (Figure 1d ), suggesting a non-cytotoxic mechanism for the observed inhibition of B95.8 cell growth.
To investigate whether AS2 oligodeoxynucleotides inhibited the expression of LMP1 gene, we determined, using indirect immuno¯uorescence, the levels of LMP1 protein in untreated cells and in cells incubated for 72 h with either antisense or non-sense LMP1 oligomers. Untreated B95.8 cells showed the typical pattern of LMP1 expression with a cytoplasm decorated by a ®nely punctuated pattern with larger and denser areas of¯uorescence at the cell membranes, in about 50% of the cell population. The level of uorescence was markedly reduced in B95.8 cells that had been incubated for 3 days with LMP1 AS2 oligomer at a ®nal concentration of 20 mM. In contrast, cells treated with LMP1 Sc2 oligomers at 20 mM maintained a pattern and a level of¯uorescence comparable to those observed in untreated cells (data not shown).
In order to quantify the variations of LMP1 protein expression, we have performed Western blot analysis of B95.8 cell extracts at 2 and 4 days after the addition to the medium of either Sc2 or AS2 oligmers. CS1-4, LMP1-speci®c monoclonal antibodies, detected a 63 kDa band, corresponding to a full-size LMP1 in the lysate of untreated B95.8 cells. In the lanes representing the cells treated with AS2 oligodeoxynucleotides the intensity of the LMP1 band gradually decreased. Densitometric analysis of the hybridization signals indicated that LMP1 expression decreased by 50% and 70% in the cell sample treated with AS2 oligomers for 2 and 4 days, respectively. The decrease of LMP1 expression is speci®cally dependent on LMP1 antisense treatment since, in several experiments, Sc2 treatment of B95.8 cells for the same length of time left the intensity of the band either unaected or slightly increased with respect to that of untreated cells. Under our experimental conditions we do not detect the truncated,`lytic' form of LMP1, whose formation, in B95.8 cells, derives from the use of an alternative promoter located within the ®rst intron (Hudson et al., 1985) . Possibly, in the absence of serum, the percentage of B95.8 cells spontaneously undergoing the lytic cycle, in which the truncated form is expressed, is very low. To verify that similar amounts of protein had indeed been loaded onto each gel track, and, furthermore, that the eect of AS2 oligomer on LMP1 protein levels was speci®c, the blots were re-hybridized with a monoclonal antibody against human ferritin. Two bands, a more intensely stained one and a weaker one, corresponding to the two ferritin subunits (21 and 19 kDa) appeared on the blots probed with this antibody. As shown in the lower panel of Figure 2 , the signals derived from the ferritin subunits are similar in all samples. Figure 2 Immunoblot determination of LMP1 protein levels in B95.8 cells exposed to LMP1 antisense oligomers. Untreated B95.8 cells and cells exposed for 2 and 4 days to either Sc2 or AS2 oligomers at 20 mM were lysed in sample buer (Rowe et al., 1987) at a concentration of 2610 7 cells/ml. Cell extracts corresponding to 4610 5 cells were subjected to polyacrylamide gel electrophoresis using a 5% stacking gel and a 10% resolving gel. Prestained molecular weight markers were loaded in parallel. After electrophoresis, proteins were blotted onto a nitrocellulose ®lter (Towbin et al., 1979) . Primary antibodies, i.e. LMP1 speci®c monoclonal antibodies CS1-4 and rabbit anti-human ferritin (Boehringer Mannheim Biochemicals) were used at a dilution of 1 : 20 and 1 : 500, respectively. Secondary antibodies, i.e. peroxidase-labelled sheep anti-mouse Ig and donkey anti-rabbit Ig were used both at a dilution of 1 : 7000. Blots treated with chemoluminescent reagents (ECL Western Blotting System, Amersham International, UK) were exposed to Kodak X-Omat ®lm according to the manufacturer's protocol3 81bp 162bp LMP1 β2-micr.
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AS2 Figure 3 Analysis of LMP1 transcripts in B95.8 cells untreated and treated with LMP1 oligomers. B95.8 cells were incubated with or without LMP1 oligomers for 3 days. Total RNA was extracted (Chomczynsky and Sacchi, 1987) in the presence of 10 mg of E. coli tRNA. RNA was reverse transcribed (Gene Amp RNA PCR kit, Perkin Elmer) after the addition of 2.5 mM poly dT tailed primer. The product of the reverse transcriptase reaction was divided into 3/4 and 1/4 and used for ampli®cation of LMP1 and b 2 -microglobulin (Manfredini et al., 1993) cDNA respectively, in the presence of 2.5 U of Taq polymerase (Perkin Elmer), and 0.15 mM of downstream and upstream primers each and 16RT ± PCR buer. Twenty microliters of the 100 ml-ampli®cation reaction mixtures were separated on a 2% agarose gel, transferred to Hybond-N nylon membrane (Amersham) and hybridized with a b 2 -microglobulin or a LMP1 oligodeoxynucleotide probe end-labelled with DIGddUTP (Boehringer Mannheim). The hybridized probes were revealed by a DIG luminescent detection kit (Boehringer Mannheim) and the speci®c signals quanti®ed by densitometric scanning after exposing the ®lters to Kodak X-OMAT AR ®lm for periods of time ranging from 2 to 12 h. The oligodeoxynucleotides primers and the probes used in the RT ± PCR reaction are reported in Table 1 The formation of a speci®c complex between DNA antisense oligomer and the target mRNA is recognized by endonuclease H that will then degrade the message. To exclude the possibility of a non-speci®c eect of the AS2 antisense oligomer, LMP1 mRNA levels were detected by RT ± PCR in B95.8 cells that had been treated for 72 h with either antisense or non-sense LMP1 oligodeoxynucleotides. Figure 3 shows that in untreated B95.8 cells LMP1 primers ampli®ed a 381 bp fragment corresponding to the LMP1 coding region, nucleotides 716 to +365. In addition, the LMP1 probe speci®c for exon 2 used in these experiments hybridized to two more bands of 458 and 280 bp, respectively. The 458 bp band also gave a positive hybridization signal with an intron 1 speci®c probe. In the absence of any ampli®cation product in RNA extracts that have not been reverse transcribed, the 458 bp fragment may result from the annealing of only ten of the 20 residues of the reverse primer (complementary to exon 2) and represent the ampli®cation of the primary (unspliced) LMP1 transcript. The lower band (280 bp) represents a single strand LMP1 ampli®cation product (data not shown). Treatment of B95.8 cells with LMP1 Sc2 oligomer yielded an LMP1 ampli®cation product virtually identical in density to that detected in untreated samples. LMP1 level resulted equally unaected in a control experiment in which AS2 oligomer was added to B95.8 cells just before RNA extraction (data not shown). By contrast, incubation of B95.8 cells with the LMP1 AS2 oligomer resulted in a dramatic decrement of signal in the ampli®cation product. In three separate experiments the intensity of the speci®c LMP1 bands was found to be diminished by 80 to 100%. The eect of the LMP1 oligomer AS2 selectively aected the expression of LMP1 gene, since the levels of bmicroglobulin mRNA as detected in a parallel RT ± PCR experiment were substantially similar in the samples. Cheung et al. (1993) have shown that antisense oligonucleotides directed to either ENBA 1 and 2 or to LMP1, prevent transformation of B lymphocytes. They reported, however, that none of the oligomers used had any eect on established EBV transformants. Our data, obtained in EBV-transformed B95.8 cells, show, by contrast, that LMP1 gene expression can be eectively down-regulated by antisense oligodeoxynucleotides also in stable transformants. We envisage that the apparent discrepancy with our results might depend on the choice of the appropriate (accessible to the antisense) mRNA target sequences or on the experimental conditions in which the cells are exposed to the oligomers.
Other studies have reported the use of antisense oligo's against EBNA1 gene expression, to inhibit proliferation of EBV immortalized cells (Roth et al., 1994) . Because of the dual role of EBNA1 in the replication of the viral genome in latent infection as well as in the regulation of the transcription of latent viral genes, it was not clear at which level of regulation suppression of the EBNA1 protein would aect the growth of EBV-infected cells. Several studies, however, have indicated LMP1 as the one EBV gene, among those expressed during latency, which has the most profound eects on cell growth (Deacon et al., 1993; Wang et al., 1985; Dawson et al., 1990; Wilson et al., 1990) . In this light, our results, by providing evidence that suppression of LMP1 gene expression by a speci®c LMP1 antisense oligodeoxynucleotide inhibits proliferation of EBVtransformed B lymphocytes, con®rm an essential involvement of LMP1 oncogene in maintaining a proliferative state in such cells.
With the exception of Burkitt's lymphoma, LMP1 is expressed in all EBV-related malignancies. Our ®ndings assert the possibility for using LMP1 antisense oligomers as therapeutics in those EBV-related types of tumors expressing the LMP1 gene at a high level.
In addition to its potential use in therapy, a block of LMP1 expression by antisense oligodeoxynucleotides may provide a useful tool to elucidate the molecular mechanisms by which LMP1 itself and other latent viral products contribute to the EBV-induced immortalization process.
